Login

Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

Important: “Obesity Blocker” Trading Action Alert

As I told you yesterday, the FDA Advisory Committee has voted to recommend what we’ve been calling “the obesity blocker.” This morning in pre-market trading, our stock is up by about 20% from its closing price of $1.52 on June 16, 2014. I still believe that it’s still incredibly undervalued. But we're not seeing the huge percentage gain in the stock price that I anticipated when I recommended you buy the stock. Why? I believe it's because the FDA Advisory Committee, despite recommending the “obesity blocker” device, dinged it with a negative vote on its efficacy.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Ray Blanco’s FDA Trader

Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Back when Paul Mampilly was growing up in India, nobody talked about the stock market. Yet as a kid, Paul read voraciously about the Great Crash of 1929 and found it fascinating.

When he turned 18, he came to the United States by himself. Since then, he’s had close to 25 years of investment...

View More By Paul Mampilly